MLC1501 Study Assessing Efficacy in Post STrOke Subjects With mOtor Deficits
Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double-blind, placebo-controlled trial of MLC1501 in
patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally
receive MLC1501 high-dose twice a day, MLC1501 low-dose twice a day, or matching placebo for
24 weeks.